Terms: = Pancreatic cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
68 results:
1. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
2. Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma.
Sun T; Gilani S; Jain D; Cai G
Diagn Cytopathol; 2023 Nov; 51(11):674-683. PubMed ID: 37469257
[TBL] [Abstract] [Full Text] [Related]
3. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.
Silvis MR; Silva D; Rohweder R; Schuman S; Gudipaty S; Truong A; Yap J; Affolter K; McMahon M; Kinsey C
J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36719686
[TBL] [Abstract] [Full Text] [Related]
4. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support pancreatic cancer Growth.
Erice O; Narayanan S; Feliu I; Entrialgo-Cadierno R; Malinova A; Vicentini C; Guruceaga E; Delfino P; Trajkovic-Arsic M; Moreno H; Valencia K; Blanco E; Macaya I; Öhlund D; Khatri P; Lecanda F; Scarpa A; Siveke JT; Corbo V; Ponz-Sarvise M; Vicent S
Clin Cancer Res; 2023 Mar; 29(6):1137-1154. PubMed ID: 36607777
[TBL] [Abstract] [Full Text] [Related]
5. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
6. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report.
Ardalan B; Azqueta JI; England J; Eatz TA
Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667063
[TBL] [Abstract] [Full Text] [Related]
7. Activating Immune Recognition in pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract] [Full Text] [Related]
8. MEK/ERK Signaling in β-Cells Bifunctionally Regulates β-Cell Mass and Glucose-Stimulated Insulin Secretion Response to Maintain Glucose Homeostasis.
Ikushima YM; Awazawa M; Kobayashi N; Osonoi S; Takemiya S; Kobayashi H; Suwanai H; Morimoto Y; Soeda K; Adachi J; Muratani M; Charron J; Mizukami H; Takahashi N; Ueki K
Diabetes; 2021 Jul; 70(7):1519-1535. PubMed ID: 33906910
[TBL] [Abstract] [Full Text] [Related]
9. Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition.
Brannon A; Drouillard D; Steele N; Schoettle S; Abel EV; Crawford HC; Pasca di Magliano M
Sci Rep; 2020 Jul; 10(1):11133. PubMed ID: 32636409
[TBL] [Abstract] [Full Text] [Related]
10. APE1 Promotes pancreatic cancer Proliferation through GFRα1/Src/ERK Axis-Cascade Signaling in Response to GDNF.
Choi YD; Jung JY; Baek M; Khan S; Song PI; Ryu S; Koo JY; Chauhan SC; Tsin A; Choi C; Kim WJ; Kim M
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32438692
[TBL] [Abstract] [Full Text] [Related]
11. Phase 1 study of the pan-HER inhibitor dacomitinib plus the mek1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM; van Brummelen EMJ; Eskens FALM; Huijberts SCFA; de Vos FYFL; Lolkema MPJK; Devriese LA; Opdam FL; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Br J Cancer; 2020 Apr; 122(8):1166-1174. PubMed ID: 32147669
[TBL] [Abstract] [Full Text] [Related]
12. Analysis of lncRNA-mRNA networks after mek1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma.
Qian J; Yang J; Liu X; Chen Z; Yan X; Gu H; Xue Q; Zhou X; Gai L; Lu P; Shi Y; Yao N
J Cell Physiol; 2020 Apr; 235(4):3657-3668. PubMed ID: 31583713
[TBL] [Abstract] [Full Text] [Related]
13. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven cancers.
Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
[TBL] [Abstract] [Full Text] [Related]
14. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
Poteet E; Liu D; Liang Z; Van Buren G; Chen C; Yao Q
PLoS One; 2019; 14(3):e0213294. PubMed ID: 30921351
[TBL] [Abstract] [Full Text] [Related]
15. Insulin promotes invasion and migration of KRAS
Wang G; Yin L; Peng Y; Gao Y; Gao H; Zhang J; Lv N; Miao Y; Lu Z
Cell Prolif; 2019 May; 52(3):e12575. PubMed ID: 30838710
[TBL] [Abstract] [Full Text] [Related]
16. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Kinsey CG; Camolotto SA; Boespflug AM; Guillen KP; Foth M; Truong A; Schuman SS; Shea JE; Seipp MT; Yap JT; Burrell LD; Lum DH; Whisenant JR; Gilcrease GW; Cavalieri CC; Rehbein KM; Cutler SL; Affolter KE; Welm AL; Welm BE; Scaife CL; Snyder EL; McMahon M
Nat Med; 2019 Apr; 25(4):620-627. PubMed ID: 30833748
[TBL] [Abstract] [Full Text] [Related]
17. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer.
Gao M; Lin M; Moffitt RA; Salazar MA; Park J; Vacirca J; Huang C; Shroyer KR; Choi M; Georgakis GV; Sasson AR; Talamini MA; Kim J
Br J Cancer; 2019 Jan; 120(1):88-96. PubMed ID: 30377341
[TBL] [Abstract] [Full Text] [Related]
18. Cinobufacini inhibits epithelial-mesenchymal transition of human hepatocellular carcinoma cells through c-Met/ERK signaling pathway.
Qi F; Wang J; Zhao L; Cai P; Tang W; Wang Z
Biosci Trends; 2018 Jul; 12(3):291-297. PubMed ID: 29794405
[TBL] [Abstract] [Full Text] [Related]
19. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Van Cutsem E; Hidalgo M; Canon JL; Macarulla T; Bazin I; Poddubskaya E; Manojlovic N; Radenkovic D; Verslype C; Raymond E; Cubillo A; Schueler A; Zhao C; Hammel P
Int J Cancer; 2018 Oct; 143(8):2053-2064. PubMed ID: 29756206
[TBL] [Abstract] [Full Text] [Related]
20. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Er JL; Goh PN; Lee CY; Tan YJ; Hii LW; Mai CW; Chung FF; Leong CO
Apoptosis; 2018 Jun; 23(5-6):343-355. PubMed ID: 29740790
[TBL] [Abstract] [Full Text] [Related]
[Next]
